Abeona Therapeutics initiated with a Buy at B. Riley FBR. B. Riley FBR analyst George Zavoico initiated Abeona Therapeutics with a Buy rating and $26 price target, citing positive early-stage clinical trial results with multiple gene therapy candidates for rare monogenic debilitating and/or fatal inherited diseases. In a research note to investors, Zavoico projected that all five of the company’s product candidates could be launched by 2024 and that Abeona could receive nearly $850M in sales with positive clinical trial results and if there are no unanticipated delays.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.